NeurAxon, Inc. to Make Multiple Presentations at the International Symposium on Nitric Oxide and Other Gaseous Neurotransm

WALTHAM, Mass.--(BUSINESS WIRE)-- NeurAxon, Inc. today announced several scientific presentations by officers and advisors to the Company at the International Symposium on Nitric Oxide and Other Gaseous Neurotransmitters, May 27 – 28, 2010 in Toronto, Ontario. NeurAxon is focused on the discovery and development of next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

The following presentations related to the Company and its technology will take place on Thursday, May 27, 2010 at the MaRS Center Auditorium in Toronto, Ontario:

  • 11:15 a.m. Presentation by John Andrews, Ph.D., Chief Scientific Officer of NeurAxon, entitled “Nitric Oxide Modulation of Sensitisation of Multiple Transmitter Systems in CNS Disorders”
  • 2:00 p.m. Presentation by Frank Porreca, Ph.D., Chairman of the NeurAxon Scientific Advisory Board, entitled Preclinical Evidence Implicating NO in Migraine Pathophysiology”
  • 3:00 p.m. Presentation by Shawn Maddaford, Ph.D., Vice President of Discovery Chemistry of NeurAxon, entitled “Crossing the Structural Barriers in the Rational Design of Single and Dual Action nNOS Inhibitors for the Treatment of Pain”
  • 3:30 p.m. Presentation by Jes Olesen, M.D., member of the NeurAxon Scientific Advisory Board, entitled “NO and CO Involvement in Migraine Pathophysiology”

About NeurAxon, Inc.

NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.



CONTACT:

MacDougall Biomedical Communications
Chris Erdman, 508-647-0209 x14

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.